KRAS and cancer: The inhibition or activation of ULK1 is often effective in overcoming cancer drug resistance to tyrosine kinase inhibitors (TKI), selective BRAF inhibitors, 5-fluorouracil (5-FU), KRAS drugs, doxorubicin, tamoxifen, and crizotinib [31].